FluoGuide announces regulatory approval from Danish Medicines Agency to commence Phase I/II clinical trial with FG001 in guiding surgery of high grade glioma including glioblastoma
Copenhagen, Denmark, 3 September 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to announce that the company has received regulatory approval for the first clinical phase I/II trial. It is the first time that our lead uPAR targeting product - FG001 - will be used to guide oncology surgery.FluoGuide appreciates that the Danish Medicines Agency wants to conduct an audit of the clinical trial site at Rigshospitalet to provide priority to patients safety as the clinical trial is a first-in-man with a new chemical entity. The first patient is therefore expected to be included in